Wells Fargo raised the firm’s price target on iRhythm to $135 from $125 and keeps an Overweight rating on the shares. On Tuesday, Signify Health announced the launch of Afib screening with Zio for at-risk patients, driving the stock up +12%. This was not contemplated in iRhythm’s 2024 guidance, though, so the firm sees potential for upside.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IRTC:
- iRhythm price target raised to $133 from $121 at Canaccord
- iRhythm price target raised to $135 from $125 at Baird
- iRhythm sees FY24 revenue $575M-$585M, consensus $581.06M
- iRhythm reports Q4 EPS (84c), consensus (60c)
- iRhythm Technologies Announces Fourth Quarter and Full Year 2023 Financial Results
